Samsung Biologics

207940.KO

702.27 USD

-3.34

-0.47%

Overview

Last close

702.27 usd

Market cap

49.98B usd

52 week high

761.21 usd

52 week low

522.84 usd

Target price

702.27 usd

Valuation

P/E

N/A

Forward P/E

57.4713

Price/Sales

16.8101

Price/Book Value

6.9969

Enterprise Value

53.69B usd

EV/Revenue

16.8129

EV/EBITDA

37.8631

Key financials

Revenue TTM

3.19B usd

Gross Profit TTM

1.60B usd

EBITDA TTM

1.35B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

11.76B usd

Net debt

643.53M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.